MedTrace Logo

Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation

NCT02877628 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2019-01-28

No results posted yet for this study

Summary

Prospective, non-randomized, open Pharmacokinetic-Pharmacogenetic-Pharmacodynamic monocentric study. Donor and recipient CYP3A5 genotype and recipient ABCB1 will not be communicate to clinicians or patients during the study.

Conditions

  • Liver Transplantation

Interventions

OTHER

Pharmacokinetic-pharmacodynamic model in liver transplantation

Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-11-29
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877628 on ClinicalTrials.gov